UNAIDS welcomes expanded rollout of HIV prevention medicine and calls for urgent action to ensure equitable and affordable global access
This image was generated by AI and may not depict real events.
UNAIDS welcomes the expanded rollout of HIV prevention medicine, lenacapavir, and calls for urgent action to ensure equitable and affordable global access. The organization urges governments, donors, and manufacturers to act with urgency to reach 20 million people with antiretroviral-based HIV prevention options by 2030.
UNAIDS commends the Global Fund to Fight AIDS, TB and Malaria and the United States for their commitment to increase access to lenacapavir, a long-acting HIV prevention medication. The initial goal was to reach 2 million people, but it has been expanded to reach 3 million people by 2028. Lenacapavir has shown to be at least 96% effective in preventing HIV and has been delivered to several countries in Africa, including Eswatini, Kenya, and South Africa. UNAIDS urges immediate acceleration of technology transfer and expansion of licensing to additional manufacturers, particularly in Africa, to ensure sustainable and affordable supply at scale. The organization stresses that reaching 20 million people with antiretroviral-based HIV prevention options by 2030 is critical to reduce new HIV infections. UNAIDS calls on governments, donors, manufacturers, and communities to act with urgency and accountability to ensure lenacapavir reaches everyone who needs it.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.